NASDAQ:MDGL

Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis

Madrigal Pharmaceuticals logo
$378.64 -18.10 (-4.56%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$393.45 +14.81 (+3.91%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)

Advanced

Key Stats

Today's Range
$377.90
▼
$399.43
50-Day Range
$378.64
▼
$540.06
52-Week Range
$353.54
▼
$615.00
Volume
327,830 shs
Average Volume
617,116 shs
Market Capitalization
$8.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$710.93
Consensus Rating
Moderate Buy

Company Overview

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company is headquartered in Conshohocken, Pennsylvania.

Its lead product, Rezdiffra (resmetirom), is a thyroid hormone receptor-beta agonist. The U.S. Food and Drug Administration approved Rezdiffra in 2024 for use with diet and exercise in adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.

Madrigal’s work centers on advancing medicines for liver disease, with Rezdiffra serving as its first approved therapy. Its commercial activities include bringing the medicine to patients in the United States.

AI Generated. May Contain Errors.

Madrigal Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

MDGL MarketRank™: 
3.87470183808 of 5 stars

Madrigal Pharmaceuticals scored higher than 77% of companies evaluated by MarketBeat, and ranked 105th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Madrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 13 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Madrigal Pharmaceuticals has a consensus price target of $710.93, representing about 87.8% upside from its current price of $378.64.

  • Amount of Analyst Coverage

    Madrigal Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Madrigal Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($2.08) to $7.30 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Madrigal Pharmaceuticals is -63.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Madrigal Pharmaceuticals is -63.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Madrigal Pharmaceuticals has a P/B Ratio of 14.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    11.16% of the float of Madrigal Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Madrigal Pharmaceuticals has a short interest ratio ("days to cover") of 7.64.
  • Change versus previous month

    Short interest in Madrigal Pharmaceuticals has recently decreased by 2.65%, indicating that investor sentiment is improving.
  • Dividend Yield

    Madrigal Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Madrigal Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Madrigal Pharmaceuticals has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Madrigal Pharmaceuticals this week, compared to 5 articles on an average week.
  • Search Interest

    12 people have searched for MDGL on MarketBeat in the last 30 days. This is an increase of 1,100% compared to the previous 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $28,352,628.00 in company stock, which represents 0.3223% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Madrigal Pharmaceuticals insiders have bought 425.07% more of their company's stock than they have sold. Specifically, they have bought $35,022,670.00 in company stock and sold $6,670,042.00 in company stock.

  • Percentage Held by Insiders

    17.60% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Madrigal Pharmaceuticals' insider trading history.
Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MDGL Stock News Headlines

My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
See More Headlines

MDGL Stock Analysis - Frequently Asked Questions

Madrigal Pharmaceuticals' stock was trading at $582.34 at the start of the year. Since then, MDGL shares have decreased by 35.0% and is now trading at $378.6410.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) posted its quarterly earnings data on Tuesday, November, 3rd. The biopharmaceutical company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $2.92. The biopharmaceutical company earned $431.27 million during the quarter, compared to analysts' expectations of $404.17 million. Madrigal Pharmaceuticals had a negative net margin of 10.89% and a negative trailing twelve-month return on equity of 27.08%.
Read the conference call transcript
.

Madrigal Pharmaceuticals' top institutional investors include State Street Corp (2.56%), William Blair Investment Management LLC (1.45%), First Trust Advisors LP (0.88%) and Pictet Asset Management Holding SA (0.80%). Insiders that own company stock include Bros Advisors Lp Baker, Rebecca Taub, William John Sibold, Paul A Friedman, Richard S Levy, Brian Joseph Lynch, Carole Huntsman, Mardi Dier, Fred B Craves, Shannon T Kelley, David Soergel, Robert E Waltermire, Kenneth Bate and James M Daly.
View institutional ownership trends
.

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Madrigal Pharmaceuticals investors own include Viking Therapeutics (VKTX), NVIDIA (NVDA), Advanced Micro Devices (AMD), Exelixis (EXEL), Tesla (TSLA), Incyte (INCY) and Intel (INTC).

Company Calendar

Last Earnings
11/03/2026
Today
11/21/2026
9th Annual Evercore ISI HealthCONx Conference
12/01/2026
38th Annual Healthcare Conference
12/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MDGL
CIK
1157601
Employees
915
Year Founded
2011

Price Target and Rating

High Price Target
$962.00
Low Price Target
$542.00
Potential Upside/Downside
+87.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($5.98)
Trailing P/E Ratio
N/A
Forward P/E Ratio
51.87
P/E Growth
N/A
Net Income
-$288.28 million
Net Margins
-10.89%
Pretax Margin
-10.89%
Return on Equity
-27.08%
Return on Assets
-12.04%

Debt

Debt-to-Equity Ratio
0.54
Current Ratio
3.05
Quick Ratio
2.78

Sales & Book Value

Annual Sales
$958.40 million
Price / Sales
9.18
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$26.99 per share
Price / Book
14.03

Miscellaneous

Outstanding Shares
23,230,000
Free Float
19,142,000
Market Cap
$8.80 billion
Optionable
Optionable
Beta
-0.98

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:MDGL) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners